Capsid Assembly Modulators: A Promising Curative Regimen for Chronic Hepatitis B

References

1. Feld J.J. Lok A.S. Zoulim F. New Perspectives on Development of Curative Strategies for Chronic Hepatitis B. Clin. Gastroenterol. Hepatol. 2023 21 8 2040 2050 10.1016/j.cgh.2023.02.032 37080262
   [Google Scholar]
2. a Gotchev D. Dorsey B.D. Nguyen D. Kakarla R. Dugan B. Chen S. Gao M. Bailey L. Liu F. Harasym T. Chiu T. Tang S. Lee A.C.H. Cole A.G. Sofia M.J. Structure–Activity Relationships and Discovery of ( S )-6-Isopropyl-2-methoxy-3-(3-methoxypropoxy)-10-oxo-5,10-dihydro-6 H -pyrido[1,2- h ][1,7]naphthyridine-9-carboxylic Acid (AB-452), a Novel Orally Available HBV RNA Destabilizer. J. Med. Chem. 2024 67 2 1421 1446 10.1021/acs.jmedchem.3c01981 38190324
   [Google Scholar]
3. b Gotchev D. Chen S. Dugan B. Dorsey B.D. Wang X. Sheraz M. Kowalski R. Liu F. Tang S. Chiu T. Harasym T. Graves I.E. Thi E.P. Mason J.D. Overholt N. Dugyala R. Lam A.M. Cole A.G. Sofia M.J. Structure–Activity Relationships and Discovery of ( S )-5-( tert -Butyl)-11-(difluoromethoxy)-9-methoxy-2-oxo-1,2,5,6-tetrahydropyrido[2′,1′:2,3]imidazo[4,5- h ]quinoline-3-carboxylic Acid (AB-161), a Novel Orally Available and Liver-Centric HBV RNA Destabilizer. J. Med. Chem. 2024 67 22 20467 20494 10.1021/acs.jmedchem.4c01928 39513566
   [Google Scholar]
4. c Jones T. Tavis J.E. Li Q. Riabova O. Monakhova N. Bradley D.P. Lane T.R. Makarov V. Ekins S. Antiviral Evaluation of Dispirotripiperazines against Hepatitis B Virus. J. Med. Chem. 2023 66 17 12459 12467 10.1021/acs.jmedchem.3c00974 37611244
   [Google Scholar]
5. d Lesch B. Birkmann A. Bonsmann S. Donald A. Engel F. Goldner T. Kumar K. Pfaff T. Urban A. Zimmermann H. Bosnidou A.E. del Castillo E. Cuevas F. Detta E. Font D. García J.G. Raymond J. Sarmentero M.Á. Cnossen A. Sinnige W. Slootweg J.C. Wegert A. Buschmann H. Discovery of AIC263282, a Hepatitis B Virus Capsid Assembly Modulator Ready for Candidate Profiling. J. Med. Chem. 2025 68 6 6361 6371 10.1021/acs.jmedchem.4c02838 40103295
   [Google Scholar]
6. e Du S. Liu X. Hu X. Zhan P. Viral Protein Dimerization Quality Control: A Design Strategy for a Potential Viral Inhibitor. J. Med. Chem. 2024 67 19 16951 16966 10.1021/acs.jmedchem.4c01540 39303015
   [Google Scholar]
7. a Wang M. Zhang J. Dou Y. Liang M. Xie Y. Xue P. Liu L. Li C. Wang Y. Tao F. Zhang X. Hu H. Feng K. Zhang L. Wu Z. Chen Y. Zhan P. Jia H. Design, Synthesis, and Biological Evaluation of Novel Thioureidobenzamide (TBA) Derivatives as HBV Capsid Assembly Modulators. J. Med. Chem. 2023 66 20 13968 13990 10.1021/acs.jmedchem.3c01022 37839070
   [Google Scholar]
8. b Cole A.G. Kultgen S.G. Mani N. Fan K.Y. Ardzinski A. Stever K. Dorsey B.D. Mesaros E.F. Thi E.P. Graves I. Tang S. Harasym T.O. Lee A.C.H. Olland A. Suto R.K. Sofia M.J. Rational Design, Synthesis, and Structure–Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836. J. Med. Chem. 2024 67 18 16773 16795 10.1021/acs.jmedchem.4c01568 39231272
   [Google Scholar]
9. c Kou B. Zhang Z. Han X. Zhou Z. Xu Z. Zhou X. Shen F. Zhou Y. Tian X. Yang G. Young J.A.T. Qiu H. Ottaviani G. Mayweg A. Zhu W. Shen H.C. Liu H. Hu T. Discovery of 4,5,6,7-Tetrahydropyrazolo[1.5-a]pyrizine Derivatives as Core Protein Allosteric Modulators (CpAMs) for the Inhibition of Hepatitis B Virus. J. Med. Chem. 2023 66 20 14116 14132 10.1021/acs.jmedchem.3c01145 37801325
   [Google Scholar]
10. Zhang W. Guo L. Liu H. Wu G. Shi H. Zhou M. Zhang Z. Kou B. Hu T. Zhou Z. Xu Z. Zhou X. Zhou Y. Tian X. Yang G. Young J.A.T. Qiu H. Ottaviani G. Xie J. Mayweg A.V. Shen H.C. Zhu W. Discovery of linvencorvir (RG7907), A Hepatitis B virus core protein allosteric modulator, for the treatment of chronic HBV infection. J. Med. Chem. 2023 66 6 4253 4270 10.1021/acs.jmedchem.3c00173 36896968
    [Google Scholar]
11. Vendeville S. Amblard F. Bassit L. Beigelman L.N. Blatt L.M. Chen X. Chou L. Kum D.B. Chanda S. Deval J. Geng X. Gupta K. Jekle A. Hu H. Hu X. Kang H. Liu C. Liu J. McGowan D.C. Misner D.L. Raboisson P. Sanchez A.A. Serebryany V. Stoycheva A.D. Symons J.A. Tan H. Vanrusselt H. Williams C. Welch M. Zhang L. Zhang Q. Zhang Y. Schinazi R.F. Smith D.B. Debing Y. The discovery and preclinical profile of ALG-000184, a Prodrug of the potent hepatitis B Virus Capsid Assembly Modulator ALG-001075. J. Med. Chem. 2024 67 23 21126 21142 10.1021/acs.jmedchem.4c01814 39575679
    [Google Scholar]
12. Berke J.M. Dehertogh P. Vergauwen K. Van Damme E. Mostmans W. Vandyck K. Pauwels F. Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B Virus. Antimicrob. Agents Chemother. 2017 61 8 e00560-17 10.1128/AAC.00560‑17 28584155
    [Google Scholar]
13. Amblard F. Boucle S. Bassit L. Chen Z. Sari O. Cox B. Verma K. Ozturk T. Ollinger-Russell O. Schinazi R.F. Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents. Bioorg. Med. Chem. 2021 31 115952 10.1016/j.bmc.2020.115952 33421915
    [Google Scholar]
14. Ma C. Chang J. Yu B. Sunlenca® (Lenacapavir): A first-in-class, long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infection. Acta Pharm. Sin. B 2024 14 12 5512 5514 10.1016/j.apsb.2024.08.009 39807316
    [Google Scholar]
15. a Zhang K. Yang X. Wang Y. Yu Y. Huang N. Li G. Li X. Wu J.C. Yang S. Artificial intelligence in drug development. Nat. Med. 2025 31 1 45 59 10.1038/s41591‑024‑03434‑4 39833407
    [Google Scholar]
16. b Ma C. Lindsley C.W. Chang J. Yu B. Rational Molecular Editing: A New Paradigm in Drug Discovery. J. Med. Chem. 2024 67 14 11459 11466 10.1021/acs.jmedchem.4c01347 38905482
    [Google Scholar]
17. c Li E.Q. Lindsley C.W. Chang J. Yu B. Molecular Skeleton Editing for New Drug Discovery. J. Med. Chem. 2024 67 16 13509 13511 10.1021/acs.jmedchem.4c01841 39133504
    [Google Scholar]